Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioMark raw data collection complete on 200 patient trial. Data will be reviewed then compiled into a report. Trial met both Health Canada and U.S. FDA standards.
BioMark receives approval from Health Canada and the Ethics Review Board for their lung cancer protocol, and will now start pilot study at CancerCare Manitoba in April.
Dr. Thomas Malcolm to head U.S. operations. Brings experience to U.S. strategy.
Ph.D in molecular biology and biochemistry, and a post doctoral fellow for both Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center.
Going to be based in Maryland, appointed head of U.S. operations, planning on gaining approval from Health Canada in 2016, then FDA approval to follow.
BioMark is a Canadian based biotech company developing a metabolic based diagnostic assay that will allow early cancer detection. BioMark currently holds a number of patents for their technology (patent no. 6811967,and patent applications for Monoclonal antibodies, and Method of Assay).
Their test uses a drug called Amantadine which is given to patients prior to analysis of their urine. The drug is acetylated using using the enzyme Spermine/Spermidine N-Acetyl Transferase (SSAT) which has been found in many cancers including lung, breast, melonomas, and GI. This method will allow for earlier detection of these cancers while minimizing costs.
Recent interview with Rahsheed Ahmed on SNN
EXECUTIVE TEAM & ADVISORS
Research/Scientific/Clinical
Dr. Daniel S. Sitar – Principal Scientific Advisor/Consultant Dr. John Yoo – Clinical Oncologist – Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of Medicine & Dentistry, Western Ontario Dr. John Schrader – Antibody development – Chair of Biomedical, Research Centre at University of British Columbia Dr. Horacio Bach – Antibody Engineering UBC Dr. Safieddin Safavi-Naeini – NSERC/BlackBerry Industrial Research Chair at University of Waterloo
Media Advisory Board
Bill Good – Veteran Broadcaster, Honorary Doctorate of Technology from BCIT
Regulatory
Dr. Ramjiawan from SBRC – Clinical Trial and Regulatory Expertise
Downstream
Jim Elliott – Downstream Technology Advisor and QMS support
North American Management
Rashid Ahmed – Founder, Chief Executive Officer Dr. Thomas Malcolm – President & Chief Scientific Officer Brian Cheng – Chief Technical Officer Abbey Abdiye – Chief Financial Officer (Canada) Neal Kaplan – Chief Financial Officer (US) Dr. Kenneth Kohn – Patent Attorney Gina Huang – Project Director
Medical Delivery Panel
Dr. James Bond – Chief of Thoracic Surgeon Surrey Hospital Dr. Dwight De Risi – Breast Oncology Surgeon Dr. Debra Hoffman – Lung Oncology Surgeon
Supporting
Dr. Reuven Gordon and Dr. Fraser Hof Canadian Research Chairs, Uvic Dr. Andrew Maksymiuk University of Manitoba and Manitoba CancerCare Dr. Samudra Dissanyake – Scientific Advisor business development Stan Lee – Chartered Accountant